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Abstract
Until recently, colonic polyps were traditionally classified as either hyperplastic or adenomatous, and
only the latter were believed to have the potential to progress to carcinoma. However, it is now
appreciated that a subset of serrated polyps also appear to have malignant potential. Serrated polyps
are a heterogeneous group of colon polyps that include hyperplastic polyps, sessile serrated
adenomas (SSAs), traditional serrated adenomas, and mixed polyps. Insights into these polyps were
derived, in part, from studies of patients with the hyperplastic polyposis syndrome. SSAs show a
predilection for the right colon, have a distinct histology, and their molecular genetic profile has
recently been linked to a pathway for colon tumorigenesis that is characterized by microsatellite
instability. Based upon available evidence, it is recommended that patients with serrated adenomas
undergo colonoscopic follow-up at the same frequency as for conventional adenomas. It is important
that physicians are aware of serrated polyps, particularly serrated adenomas and their relationship to
colon cancer, and their proper clinical management.
Introduction and context
Colon cancer is the fourth most common cause of
cancer and is second only to lung cancer as a cause of
cancer mortality in the United States [1]. Colon cancers
are believed to develop from polyps and, until
recently, the adenoma was considered the exclusive
precursor lesion while hyperplastic polyps (HPPs) were
deemed to have no malignant potential. However,
accumulated evidence suggested that a subset of HPPs
are associated with cancers. Such evidence includes the
finding of hyperplastic tissue at the margin of
adenomas and the association of larger HPPs, particu-
larly in the right colon, with carcinoma [2-4]. In 1990,
Longacre and Fenoglio-Preiser [5] analyzed a group of
polyps with features similar to HPPs and adenomas
and concluded that most of these cases were actually
adenomas with a serrated morphology, which led to
the term ‘serrated adenoma’. These serrated polyps
have a sawtooth pattern of crypt infolding as a distinct
histological feature (Figure 1).
In the late 1970s, reports of colon cancer developing in
patients with numerous colonic HPPs began to come to
light. This characteristic condition was later termed
hyperplastic polyposis syndrome (HPS) [2-4,6-8]. It is
now accepted that patients with HPS are at increased risk
for colorectal cancer [6,8]. An analysis of polyps from
patients with HPS by Torlakovic et al. [9] found that the
morphology of these polyps differed from the usual
small HPPs that are typically seen in the left colon. These
lesions seen in patients with HPS were morphologically
distinct and included serration and architectural distor-
tion, and some had areas of cytologic dysplasia. Thus, the
term sessile serrated adenoma (SSA) was coined in 2003
to distinguish these polyps from traditional serrated
adenomas (TSAs) [9]. SSAs are typically characterized
histologically by the extension of the serrations to the
crypt base and dilated L or inverted T-shaped crypts [10].
Today, the term serrated polyp has become an umbrella
term that encompasses HPPs, TSAs, SSAs, and mixed
polyps (mixed polyps consist of SSAs with focal areas of
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that, under certain circumstances, a serrated polyp can
become cancerous when an HPP evolves into an SSA,
then to a mixed polyp, and finally to a serrated colon
cancer, as discussed below [7,11,12]. In addition, studies
have suggested that the presence of a large serrated
polyp is predictive of synchronous advanced colorectal
neoplasia [13].
Accumulating evidence indicates that SSAs may be a
precursor lesion for sporadic colon cancers with high-
frequency microsatellite instability (MSI-H) [11,14,15].
As such, both are more common in the proximal colon
and are found in women more often than men [16].
In a histologic analysis of lesions previously described
as HPPs and removed at sites where MSI-H cancers were
later diagnosed, such polyps were later reclassified as
SSAs [17]. While the majority (80-85%) of colon cancers
arise from adenomatous polyps through a classical
pathway characterized by chromosomal instability, a
subset (15-20%) develop via an alternative pathway
characterized by MSI-H that is due to deficient DNA mis-
match repair (MMR) [18-20]. In sporadic cases, MSI-H is
due to the inactivation of the MMR gene MLH1 by DNA
hypermethylation, whereas in Lynch Syndrome (also
called hereditary nonpolyposis colorectal cancer), MSI-H
is due to a germline mutation in an MMR gene [19-21].
SSAs share common molecular features with sporadic
MSI-H cancers, including a high rate of activating
mutations in the BRAF gene and hypermethylation of
multiple genes, a characteristic termed the ‘CpG island
methylator phenotype’ (CIMP) [14,15]. BRAF mutations
are not found in MSI-H colon cancers from patients with
Lynch Syndrome, and therefore can be used to distin-
guish sporadic tumors from germline MSI-H tumors.
Mutations in BRAF have been shown to be mutually
exclusive with KRAS mutations [14,17,22,23].
Recent advances
There are distinct histological and genetic differences
between serrated polyps and conventional adenomas
(Figure 1 and Figure 3). Histologically and by definition,
all conventional adenomas show epithelial dysplasia,
whereas SSAs often display cytological atypia or dyspla-
sia but not the classical dysplastic morphology of
conventional adenomas [9-11]. TSAs and mixed polyps
Figure 1. Histology of a serrated polyp
Arrows highlight the sawtooth configuration.
Figure 2. Types of serrated polyp
HPP, hyperplastic polyp; MP, mixed polyp; SSA, sessile serrated adenoma;
TSA, traditional serrated adenoma.
Figure 3. A conventional colonic adenoma showing dysplastic
epithelia
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differentiated from conventional adenomas by their
histology [10,11]. In recent years, there has been a
heightened interest in the serrated adenoma pathway,
but the lack of uniform terminology and histological
interobserver agreement has hampered accurate esti-
mates of the frequency of serrated polyps [10]. Chro-
moendoscopy has been shown to enhance mucosal
detail and lesion detection [24,25]. In two recent studies,
one of which utilized chromoendoscopy, the frequency
of serrated polyps was estimated to be as follows: HPPs
were seen in ~30% of patients, SSAs in 4-9%, TSAs in
~0.7%, and mixed polyps in 0.7-1.7% [16,26].
Colonoscopy with polypectomy has been shown to
decrease the incidence and mortality associated with
colorectal cancer [27,28]. Interestingly, studies have
shown that interval colon cancers, defined as colon
cancers that develop within 5 years of a colonoscopy, are
more likely to be located in the right colon and to show
MSI-H [10,11,22]. SSAs may be the precursor lesions for
MSI-H colon cancers, which account for approximately
15% of new colon cancer diagnoses [11,14,15]. This link
is strongest at the molecular level, given the presence of
CIMP and mutations in BRAF in both SSAs and
established MSI-H colon cancers. In a large retrospective
study conducted in Canada, Baxter et al. [29] found that
colonoscopy decreases mortality from left-sided but not
right-sided colon cancers. While the explanation for the
reduced effectiveness of colonoscopy for detecting right-
sided lesions remains unclear, it is tempting to speculate
that SSAs may contribute to missed lesions as they are
mostly sessile, generally right-sided, and appear to
be precursors of MSI-H colon cancers [14,17,22,23,30].
However, to date, there is limited data on the natural
history and rate of progression of serrated adenomas to
colon cancer. Until more is known about their natural
history, colon cancer surveillance guidelines remain the
same for patients found to have serrated adenomas as
those with conventional adenomas. The crucial factors
that guide the interval and frequency of surveillance
colonoscopy are the size and number of polyps and the
degree of mucosal dysplasia [31].
Implications for clinical practice
The discovery that serrated polyps are a distinct
histological entity and that a subset are associated with
a risk of progression to colon cancer has lead to a
paradigm shift in our understanding of colon polyps.
Serrated polyps include hyperplastic lesions with cyto-
logical dysplasia distinct from that associated with
conventional colonic adenomas, and are referred to as
serrated adenomas. Among the more important findings
is that SSAs may be the precursor lesions for MSI-H colon
cancers. Furthermore, there is evidence that serrated
polyps are more likely to be missed during colonoscopy
[10,11,22]. As a result, colonoscopic follow-ups for
serrated adenomas should be the same as for conven-
tional adenomatous polyps. Future challenges include
enhancing polyp recognition and improving uniformity
in the pathological interpretation of serrated polyps.
Another vital challenge will be to improve detection and
complete removal of serrated polyps during endoscopy.
Meeting these challenges while maintaining vigilant
colonoscopic surveillance are essential steps toward
colon cancer prevention.
Abbreviations
CIMP, CpG island methylator phenotype; HPP, hyper-
plastic polyp; HPS, hyperplastic polyposis syndrome;
MMR, mismatch repair; MSI-H, high-frequency micro-
satellite instability; SSA, sessile serrated adenoma; TSA,
traditional serrated adenoma.
Competing interests
The authors declare that they have no competing
interests.
Acknowledgements
Photographs courtesy of Thomas Smyrk, MD.
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer
J Clin 2010, 60:277-300.
2. Bengoechea O, Martinez-Penuela JM, Larrinaga B, Valerdi J, Borda F:
Hyperplastic polyposis of the colorectum and adenocarci-
noma in a 24-year-old man. Am J Surg Pathol 1987, 11:323-7.
3. Cooper HS, Patchefsky AS, Marks G: Adenomatous and carcino-
matous changes within hyperplastic colonic epithelium. Dis
Colon Rectum 1979, 22:152-6.
4. Whittle TS, Jr, Varner W, Brown FM: Giant hyperplastic polyp of
the colon simulating adenocarcinoma. Am J Gastroenterol 1978,
69:105-7.
5. Longacre TA, Fenoglio-Preiser CM: Mixed hyperplastic adeno-
matous polyps/serrated adenomas. A distinct form of color-
ectal neoplasia. Am J Surg Pathol 1990, 14:524-37.
6. Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J:
Hyperplastic polyposis: association with colorectal cancer.
Am J Surg Pathol 2001, 25:177-84.
7. O’Brien MJ: Hyperplastic and serrated polyps of the color-
ectum. Gastroenterol Clin North Am 2007, 36:947-68.
8. Place RJ, Simmang CL: Hyperplastic-adenomatous polyposis
syndrome. J Am Coll Surg 1999, 188:503-7.
9. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM:
Morphologic reappraisal of serrated colorectal polyps. Am J
Surg Pathol 2003, 27:65-81.
10. Leggett B, Whitehall V: Role of the serrated pathway in
colorectal cancer pathogenesis. Gastroenterology 2010,
138:2088-100.
11. Groff RJ, Nash R, Ahnen DJ: Significance of serrated polyps of
the colon. Curr Gastroenterol Rep 2008, 10:490-8.
12. Jass JR, Smith M: Sialic acid and epithelial differentiation in
colorectal polyps and cancer—a morphological, mucin and
lectin histochemical study. Pathology 1992, 24:233-42.
Page 3 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:89 http://f1000.com/reports/m/2/8913. Li D, Jin C, McCulloch C, Kakar S, Berger BM, Imperiale TF,
Terdiman JP: Association of large serrated polyps with
synchronous advanced colorectal neoplasia. Am J Gastroenterol
2009, 104:695-702.
14. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV,
Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N,
Tanaka N, Higuchi T, Young J, Jass JR, Leggett BA: BRAF mutation is
associated with DNA methylation in serrated polyps and
cancers of the colorectum. Gut 2004, 53:1137-44.
15. O’Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E,
Amorosino M, Farraye FA: Comparison of microsatellite
instability, CpG island methylation phenotype, BRAF and
KRAS status in serrated polyps and traditional adenomas
indicates separate pathways to distinct colorectal carcinoma
end points. Am J Surg Pathol 2006, 30:1491-501.
16. Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VL, Pike T,
Simms LA, Young J, James M, Montgomery GW, Appleyard M,
Hewett D, Togashi K, Jass JR, Leggett BA: High prevalence of
sessile serrated adenomas with BRAF mutations: a prospec-
tive study of patients undergoing colonoscopy. Gastroenterology
2006, 131:1400-7.
17. Goldstein NS: Serrated pathway and APC (conventional)-type
colorectal polyps: molecular-morphologic correlations,
genetic pathways, and implications for classification. Am J
Clin Pathol 2006, 125:146-53.
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC,
Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic
alterations during colorectal-tumor development. N Engl J
Med 1988, 319:525-32.
19. Abdel-Rahman WM, Peltomaki P: Molecular basis and diagnostics
of hereditary colorectal cancers. Ann Med 2004, 36:379-88.
20. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl
J Med 2003, 348:919-32.
21. Abdel-Rahman WM, Peltomaki P: Lynch syndrome and related
familial colorectal cancers. Crit Rev Oncog 2008, 14:1-22;
discussion 23-31.
22. Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH,
Shaukat A: CIMP status of interval colon cancers: another
piece to the puzzle. Am J Gastroenterol, 105:1189-95.
23. Kim YH, Kakar S, Cun L, Deng G, Kim YS: Distinct CpG island
methylation profiles and BRAF mutation status in serrated
and adenomatous colorectal polyps. Int J Cancer 2008,
123:2587-93.
24. Lee JH, Kim JW, Cho YK, Sohn CI, Jeon WK, Kim BI, Cho EY:
Detection of colorectal adenomas by routine chromoendo-
scopy with indigocarmine. Am J Gastroenterol 2003, 98:1284-8.
25. Trecca A, Gai F, Di Lorenzo GP, Hreniuc H, Pasciuto A, Antonellis F,
Sperone M: [Conventional colonoscopy versus chromoendo-
scopy and magnifying endoscopy for the diagnosis of color-
ectal lesions: a comparative prospective study in 995
patients]. Chir Ital 2004, 56:31-6.
26. Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL: Serrated and
non-serrated polyps of the colorectum: their prevalence in an
unselected case series and correlation of BRAF mutation
analysis with the diagnosis of sessile serrated adenoma. J Clin
Pathol 2009, 62:516-8.
27. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN: Screening for
colorectal cancer in adults at average risk: a summary of the
evidence for the U.S. Preventive Services Task Force. Ann
Intern Med 2002, 137:132-41.
28. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B,
Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D,
Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D,
Rex DK; US Multi-Society Task Force on Colorectal Cancer;
American Cancer Society: Guidelines for colonoscopy surveil-
lance after polypectomy: a consensus update by the US Multi-
Society Task Force on Colorectal Cancer and the American
Cancer Society. Gastroenterology 2006, 130:1872-85.
29. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR,
Rabeneck L: Association of colonoscopy and death from
colorectal cancer. Ann Intern Med 2009, 150:1-8.
F1000 Factor 8
Evaluated by Brenda Hoffman 26 Mar 2009
30. Ward RL, Cheong K, Ku SL, Meagher A, O’Connor T, Hawkins NJ:
Adverse prognostic effect of methylation in colorectal cancer
is reversed by microsatellite instability. J Clin Oncol 2003,
21:3729-36.
31. East JE, Saunders BP, Jass JR: Sporadic and syndromic hyperplas-
tic polyps and serrated adenomas of the colon: classification,
molecular genetics, natural history, and clinical manage-
ment. Gastroenterol Clin North Am 2008, 37:25-46.
Page 4 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:89 http://f1000.com/reports/m/2/89